{"title":"2021-2022 Drug Updates in Solid Tumors.","authors":"Kirollos Hanna","doi":"10.6004/jadpro.2023.14.3.9","DOIUrl":null,"url":null,"abstract":"<p><p>During JADPRO Live 2022, Kirollos Hanna, PharmD, BCPS, BCOP, briefed advanced practitioners on key FDA approvals from late 2021 to late 2022. He described mechanisms of action that are unique across some malignancies, as well as mechanisms of action that clinicians can utilize through an expanded indication or across other solid malignancies. Finally, he discussed safety profiles and what advanced practitioners can and should do in monitoring across solid tumors.</p>","PeriodicalId":17176,"journal":{"name":"Journal of the Advanced Practitioner in Oncology","volume":"14 3","pages":"227-231"},"PeriodicalIF":0.0000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8f/36/jadpro-14-227.PMC10184837.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Advanced Practitioner in Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.6004/jadpro.2023.14.3.9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
During JADPRO Live 2022, Kirollos Hanna, PharmD, BCPS, BCOP, briefed advanced practitioners on key FDA approvals from late 2021 to late 2022. He described mechanisms of action that are unique across some malignancies, as well as mechanisms of action that clinicians can utilize through an expanded indication or across other solid malignancies. Finally, he discussed safety profiles and what advanced practitioners can and should do in monitoring across solid tumors.